Spectrum Medical | Danville, VA
Status
Conditions
Treatments
About
This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15).
Full description
All subjects will have a screening visit and a treatment visit followed by six follow-up visits: 10 days, 6 weeks, 3 months, 6 months, 9 months, and 12 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
45 participants in 2 patient groups
Loading...
Central trial contact
Teresa M Reisig, MS, CCRP; Melissa Hirschberg, BSN, CCRA
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal